---
id: CRE-carbapenem-resistant-Enterobacterales_072
category: organisms
tags: [CRE, carbapenem-resistant, KPC, NDM, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Carbapenem-Resistant Enterobacterales (CRE)

**Q:** What are the resistance mechanisms, treatment strategies (by carbapenemase type), and management of CRE infections?

**A:**

**Definition:**
- **CRE:** Enterobacterales resistant to carbapenems (meropenem, imipenem, or doripenem MIC ≥4 μg/mL)
- **Nightmare bacteria** (CDC designation)
- High mortality (40-60% for bloodstream infection)

**Organisms:**
- **Klebsiella pneumoniae** (most common)
- **E. coli**
- Enterobacter spp., Citrobacter spp., Serratia spp.

---

**Carbapenem Resistance Mechanisms:**

**1. Carbapenemases (Most Important):**

| **Class** | **Type** | **Examples** | **Geography** | **β-Lactamase Inhibitor Susceptible?** |
|-----------|----------|--------------|---------------|----------------------------------------|
| **Class A** | Serine carbapenemase | **KPC** (most common in US) | US, Europe, Latin America | ✅ Yes (avibactam, vaborbactam, relebactam) |
| **Class B** | Metallo-β-lactamase (MBL) | **NDM**, VIM, IMP | India, Balkans, Middle East | ❌ No (resistant to all BL/BLI except aztreonam) |
| **Class D** | OXA-type | **OXA-48** | Europe, Middle East, North Africa | Partial (avibactam) |

**Key Point:** **Identifying carbapenemase type is CRITICAL** for treatment selection

**2. Non-Carbapenemase Mechanisms (Less Common):**
- **ESBL + porin loss** (still carbapenem-susceptible by MIC, but clinical failure possible)
- **AmpC hyperproduction + porin loss**

---

**Epidemiology & Risk Factors:**

**Patient Risk Factors:**
- Prolonged hospitalization (ICU)
- Multiple antibiotic exposures (especially carbapenems)
- Invasive devices (central lines, ventilators, urinary catheters)
- Organ transplantation
- International travel/healthcare (India, Greece, Israel, Italy)
- Prior CRE colonization

**US Prevalence:**
- **1-5% of Enterobacterales** (increasing)
- **KPC = most common** carbapenemase in US (70-80%)
- **NDM increasing** (often travel-associated)

---

**Clinical Syndromes:**

**1. Bloodstream Infection:**
- Mortality: 40-60% (even with appropriate therapy)
- Often catheter-associated (CLABSI)

**2. Urinary Tract Infection:**
- Catheter-associated (CAUTI)
- Can be less severe than BSI (mortality 10-20%)

**3. Pneumonia (VAP/HAP):**
- High mortality (50-70%)

**4. Intra-Abdominal Infection:**
- Post-surgical, biliary tract
- Requires source control + antibiotics

---

**Treatment:**

**Key Principle:** **Treatment depends on carbapenemase type** (KPC vs NDM)

**IDSA 2024 Guidance:** Identify carbapenemase mechanism to guide therapy

---

**1. KPC-Producing CRE (Most Common in US):**

**First-Line Options (Choose Based on Availability):**

| **Agent** | **Dosing** | **Efficacy** | **Notes** |
|-----------|------------|--------------|-----------|
| **Ceftazidime-avibactam (CAZ-AVI)** | 2.5g IV q8h (2h infusion) | 98-99% susceptible | Broad KPC coverage<br>Also covers OXA-48 |
| **Meropenem-vaborbactam (M-V)** | 4g IV q8h (3h infusion) | 98-99% susceptible | **Most potent** vs KPC<br>Does NOT cover OXA-48, NDM |
| **Imipenem-relebactam (I-R)** | 500/250 mg IV q6h (30 min infusion) | ~90% susceptible | Alternative<br>Does NOT cover OXA-48, NDM |

**Efficacy Comparison:**
- **All three agents:** Clinical success ~80%, 30-day mortality ~12% (comparable)
- **No single preferred agent** for KPC (IDSA 2024)

**Combination Therapy:**
- **Monotherapy preferred** for uncomplicated infections
- **Combination consider for:**
  - Severe sepsis/shock
  - High inoculum (pneumonia)
  - Concern for heteroresistance

**Common Combinations:**
- CAZ-AVI + aminoglycoside (gentamicin/amikacin)
- CAZ-AVI + colistin
- CAZ-AVI + fosfomycin

---

**2. NDM-Producing CRE (MBL):**

**Key Point:** **CAZ-AVI, M-V, I-R are INEFFECTIVE** against NDM (metallo-β-lactamases)

**First-Line Options:**

**A. Ceftazidime-Avibactam + Aztreonam (CAZ-AVI + ATM):**

**Rationale:**
- **Aztreonam:** NOT hydrolyzed by MBL (unique β-lactam)
- **Avibactam:** Protects aztreonam from other β-lactamases (ESBL, AmpC)
- **Synergistic combination**

**Dosing:**
- **Ceftazidime-avibactam:** 2.5g IV q8h
- PLUS **Aztreonam:** 2g IV q8h (can infuse together)

**Efficacy:**
- **Observational data:** 30-day mortality 19% (vs 44% with alternative regimens)

**B. Cefiderocol (Siderophore Cephalosporin):**

**Dosing:**
- **Cefiderocol:** 2g IV q8h (3h infusion)

**Efficacy:**
- **100% active** against KPC-producing CRE
- **Only 58% active** against NDM-producing CRE
- **Concern:** Higher mortality signal in some trials (CREDIBLE-CR, APEKS-NP)

**Role:**
- **Alternative** for NDM-CRE (if CAZ-AVI + aztreonam unavailable)
- **Monotherapy** acceptable for some infections

**C. Polymyxins (Colistin) + Combination:**

**Last-Resort Option:**
- **Colistin:** 300 mg loading, then 150 mg IV q12h
- ALWAYS in combination (colistin + tigecycline, colistin + aminoglycoside, colistin + aztreonam)
- **High toxicity** (nephrotoxic, neurotoxic)
- **Resistance emerging** (5-10%)

---

**3. OXA-48-Producing CRE:**

**Treatment:**
- **Ceftazidime-avibactam** (covers OXA-48)
- **NOT covered by:** Meropenem-vaborbactam, imipenem-relebactam
- Alternative: Cefiderocol

---

**4. Treatment by Syndrome:**

**Urinary Tract Infection (CRE):**
- **KPC:** CAZ-AVI, M-V, or I-R (5-14 days)
- **NDM:** CAZ-AVI + aztreonam OR cefiderocol
- **Alternative (cystitis only):** Fosfomycin (if susceptible), aminoglycoside (if susceptible - NOT for upper tract)

**Bloodstream Infection (CRE):**
- **KPC:** CAZ-AVI, M-V, or I-R (7-14 days)
- **NDM:** CAZ-AVI + aztreonam (preferred) OR cefiderocol
- Remove source (catheter)
- Consider combination for severe sepsis

**Pneumonia (CRE):**
- **KPC:** CAZ-AVI OR M-V (7-14 days)
- **NDM:** CAZ-AVI + aztreonam OR cefiderocol
- **Combination preferred** (high inoculum, poor outcomes)
- Consider adjunctive inhaled aminoglycoside or colistin

**Intra-Abdominal Infection (CRE):**
- **Source control essential** (drainage, surgery)
- CAZ-AVI, M-V, or I-R (KPC)
- CAZ-AVI + aztreonam (NDM)
- Duration: 4-7 days (post-source control)

---

**Resistance to New Agents:**

**Emerging Concerns:**
- **CAZ-AVI resistance:** 1-5% (KPC variants with D179Y mutation)
- **M-V resistance:** Rare (<1%)
- **Cefiderocol resistance:** Variable (especially NDM)

**Pan-Drug Resistant (PDR) CRE:**
- Resistant to ALL available agents
- **Options:** Colistin + combination, experimental agents (plazomicin, eravacycline)

---

**Comparison: Treatment by Carbapenemase Type**

| **Carbapenemase** | **First-Line** | **Alternative** | **AVOID** |
|-------------------|----------------|-----------------|-----------|
| **KPC** (Class A) | **CAZ-AVI**, M-V, I-R | Cefiderocol | Ertapenem/meropenem |
| **NDM** (Class B, MBL) | **CAZ-AVI + aztreonam** | Cefiderocol | CAZ-AVI alone, M-V, I-R |
| **OXA-48** (Class D) | **CAZ-AVI** | Cefiderocol | M-V, I-R |

---

**Infection Control:**

**Contact Precautions:**
- Gown and gloves
- Private room (or cohort)
- Dedicated equipment

**Screening:**
- Rectal swab screening for high-risk patients (prior CRE, international healthcare)

**Antibiotic Stewardship:**
- **Limit carbapenem use** (prevent CRE emergence)
- Use narrow-spectrum agents when possible

---

**Prognosis:**

**Mortality:**
- **Bloodstream infection:** 40-60%
- **Pneumonia:** 50-70%
- **UTI:** 10-20%

**Predictors of Mortality:**
- Inappropriate empiric therapy
- Delayed source control
- Severe sepsis/shock
- High APACHE II score

---

**Diagnostic Testing:**

**Carbapenemase Detection:**
- **Phenotypic tests:** Modified Hodge test (outdated), Carba NP test
- **Molecular tests:** PCR (detects KPC, NDM, OXA-48, VIM, IMP genes)
- **MALDI-TOF:** Carbapenemase detection (some platforms)

**Key Point:** **Rapid carbapenemase identification** → appropriate therapy selection

---

**Mnemonic: "CRE = Carbapenemase Really Matters (KPC vs NDM)"**
- **C**arbapenemase type determines treatment
- **R**esistant to carbapenems
- **E**nterobacterales (K. pneumoniae, E. coli)

**Mnemonic: "KPC = Kills Promptly, Choose CAZ-AVI/M-V/I-R"**
- **K**PC = Class A
- **C**hoose CAZ-AVI, M-V, or I-R (all work)

**Mnemonic: "NDM = Needs Double coverage (CAZ-AVI + Aztreonam)"**
- **N**DM = MBL (Class B)
- **D**ouble = CAZ-AVI + aztreonam
- **M**ust avoid CAZ-AVI alone, M-V, I-R (ineffective)

**Clinical Pearls:**
- **Identify carbapenemase type** (KPC vs NDM) - critical for treatment selection
- **KPC (most common in US):** CAZ-AVI, M-V, or I-R (all ~80-90% success)
- **NDM:** CAZ-AVI + aztreonam (preferred) OR cefiderocol (alternative)
- **M-V does NOT cover NDM or OXA-48** (only KPC)
- **CAZ-AVI covers KPC and OXA-48** (but NOT NDM alone)
- **Aztreonam is the ONLY β-lactam stable to MBL** (but needs avibactam to protect from ESBL/AmpC)
- **Cefiderocol** active against KPC (100%) but only 58% against NDM
- **Mortality 40-60%** even with appropriate therapy (BSI)
- **Source control essential** (remove catheters, drain abscesses)
- **Combination therapy** for severe sepsis, pneumonia, high inoculum
- **Pan-drug resistant CRE emerging** (1-5% CAZ-AVI resistance)
- **Contact precautions mandatory** (prevent transmission)
- **Limit carbapenem use** to prevent CRE (stewardship)

**Media:** None

**Sources:** [IDSA 2024 - AMR guidance], [Korean IC Journal 2024 - CRE treatment guidelines], [PMC 2024 - Treatment for CRE recent advances], [PMC 2024 - Meropenem-vaborbactam review], [PMC 2025 - CAZ-AVI activity vs KPC-2], [Contagion Live 2024 - Preferred BL/BLI for KPC], [PMC 2021 - CRE considerations new antimicrobials]
